Historique
Détail de l'auteur
Documents disponibles écrits par cet auteur (3)
Ajouter le résultat à votre sélection Affiner la recherche
H. FRASER ; N. K. MARTIN ; H. BRUMMER-KORVENKONTIO ; P. CARRIERI ; O. DALGARD ; J. DILLON ; D. GOLDBERG ; S. HUTCHINSON ; M. JAUFFRET-ROUSTIDE ; M. KABERG ; A. A. MATSER ; M. MATICIC ; H. MIDGARD ; V. MRAVCIK ; A. OVREHUS ; M. PRINS ; J. REIMER ; G. ROBAEYS ; B. SCHULTE ; D. K. VAN SANTEN ; R. ZIMMERMANN ; P. VICKERMAN ; M. HICKMAN | 2018
Dans Journal of Hepatology (Vol.68, n°3, March 2018) Article : PériodiqueBACKGROUND & AIMS: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opio[...]Nouveauté![Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses [Viewpoint]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=79379)
J. V. LAZARUS ; K. SAFREED-HARMON ; S. R. STUMO ; M. JAUFFRET-ROUSTIDE ; M. MATICIC ; T. REIC ; E. SCHATZ ; J. TALLADA ; M. HARRIS ; HEP-CORE STUDY GROUP | 2017
Dans International Journal of Drug Policy (Vol.47, September 2017) Article : PériodiqueIn 2016, the World Health Organization (WHO) called for the elimination of viral hepatitis as a public health threat and established the ambitious targets of achieving an 80% reduction in new infections and a 65% reduction in deaths from hepatit[...]
M. MATICIC ; Z. PIRNAT ; A. LEICHT ; R. ZIMMERMANN ; T. WINDELINCK ; M. JAUFFRET-ROUSTIDE ; E. DUFFELL ; T. TAMMI ; E. SCHATZ | 2020
Dans Harm Reduction Journal (Vol.17, 2020) Article : PériodiqueBackground: People who inject drugs (PWID) account for the majority of new cases of hepatitis C virus (HCV) infection in Europe; however, HCV testing, and treatment for PWID remain suboptimal. With the advent of direct acting antivirals (DAAs) t[...]
